Squamous Cell Carcinoma of Head and Neck Clinical Trial
Official title:
A Phase 2, Open-label, Multicenter Study Investigating Oncolytic Immunotherapy in Combination With Other Therapy in Patients With Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Verified date | December 2023 |
Source | Replimune Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 2, multicenter, open-label, 2-cohort (Locoregionally Advanced Cohort or Recurrent/Metastatic Cohort) study evaluating RP3 in combination with concurrent chemoradiation therapy (CCRT) followed by nivolumab (for the LA Cohort) or combined with chemotherapy and nivolumab (for the R/M Cohort) in patients with advanced, inoperable squamous cell carcinomas of the head and neck (SCCHN), including of the oral cavity, oropharynx, hypopharynx, larynx, or unknown primary.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 1, 2026 |
Est. primary completion date | March 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histological diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx or of a lymph node(s) anywhere in levels I to V of the neck that has been excluded clinically from association with cancer from a non-head and neck site - All patients Must be willing to consent to provide archival or fresh tumor biopsy samples obtained within 60 days prior to initiation of study treatment. Patients must also consent to provide on-treatment biopsies as per protocol. - At least 1 measurable lesion of = 1 cm in longest diameter (or shortest diameter for lymph nodes), in accordance with RECIST. - At least injectable tumors of at least 1 cm in aggregate overall longest diameter. - Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 -1. Locally Advanced Cohort Only • patients must not be amenable to surgery with curative intent Previously untreated high-risk disease meeting at least 1 of the following criteria: - Oral cavity, hypopharynx, larynx, oropharynx (p16 negative): Stage III/ IV Note: Cancers of the oral cavity, hypopharynx, and larynx are eligible irrespective of p16 status. These patients will not be stratified by p16 status. - For p16 positive oropharynx cancers, patients must have either - T3 and/or N2 or greater disease with active smoking and/or greater than 20 pack year smoking history OR - T4 and/or N3 disease irrespective of tobacco use - SCCHN of unknown primary Stage III/IV irrespective of p16 status or smoking status. - Eligible for definitive CCRT with curative intent. R/M Cohort Only - Has recurrent or metastatic SCCHN eligible for first line systemic therapy for R/M disease. - Has a PD-L1 CPS <20. Exclusion Criteria: - Primary tumors of nasopharynx, paranasal sinuses, nasal passages, salivary gland, thyroid or parathyroid gland, or skin. - Tumors with histopathology indicating the tumor has sarcomatous, sarcomatoid, verrucous, mixed, undifferentiated, or otherwise nonsquamous components. - Has an airway that is not deemed safe and stable on flexible fiberoptic laryngoscopy (FFL) performed by a head & neck cancer specialist within 7 days of first RP3 injection. - Has a baseline serum albumin (at Screening) <2.5 g/dL and/or evidence of cachexia or muscle wasting during physical exam at Screening. - Known acute or chronic hepatitis B or acute or chronic hepatitis C - Systemic infection requiring intravenous (IV) antibiotics - Active significant herpetic infections or prior complications of HSV-1 infection (eg, herpetic keratitis or encephalitis) - History of interstitial lung disease. - History of (noninfectious) pneumonitis that required steroids or has current pneumonitis. - Patients who require intermittent or chronic use of systemic (oral or IV) antivirals with known antiherpetic activity (eg, acyclovir). - Administration of live vaccine within 28 days prior to the first dose of study treatment. - History of allergy or sensitivity to study drug components or prior monoclonal antibody treatment. - History of life-threatening toxicity related to prior immune treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways - History of viral infections according to the protocol - Treatment with botanical preparations within 2 weeks prior to treatment. - Major surgery = 2 weeks prior to starting study treatment. LA Cohort only - Has received prior radiotherapy for SCCHN. - Has received any prior systemic therapy for SCCHN. R/M cohort only - Is eligible for radiation and/or surgery with curative intent. - Has received systemic therapy for recurrence or new (ie, not present at the time of initial diagnosis) metastases of SCCHN. - Received a paclitaxel-containing regimen as part of frontline treatment (prior to R/M disease) with a documented best response of stable disease (SD) or PD (patients who achieved a partial response [PR] or CR are eligible). - Received a carboplatin-containing regimen as part of frontline treatment (prior to R/M disease) with a documented best response of SD or PD (patients who achieved PR or CR are eligible). - Patients with known intolerance to carbo-platinum and/or paclitaxel, including hypersensitivity to Cremophor® EL (polyoxyethylated castor oil). - Previously received multiple courses of irradiation to the same anatomic site unless such patient has nondoubly-irradiated, measurable, injectable lesions, which are the only lesions to be used as target lesions (for nodal disease, only lesions in nodal basins that have been previously irradiated just once or not irradiated at all may be injected and/or used as target lesions). Note: Other protocol defined inclusion/exclusion criteria apply for each cohort |
Country | Name | City | State |
---|---|---|---|
Czechia | University Hospital Olomouc | Olomouc | |
Czechia | Fakultni Thomayerova Nemocnice | Prague | |
Czechia | FN Kralovske Vinohrady | Praha | |
France | Centre Georges Francois Leclerc, Department of Oncology | Dijon | |
France | Centre Leon Berard | Lyon | |
France | Assistance Publique Hopitaux De Marseille | Marseille | |
France | CHU Nimes, Instiut de Cancerologie du Gard, Medical Oncology | Nîmes | |
France | Institut Gustave Roussy Paris | Villejuif | |
Germany | Charite University Hospital of Berlin, Comprehensive Cancer Center | Berlin | |
Germany | Universitatsklinik Jena Klinik und Poliklinik fur Hals-, Nasen - und Ohrenheilkunde | Jena | |
Germany | University Hospital Leipzig Clinic and Polyclinic for otorhinolaryngology | Leipzig | |
Germany | LMU Klinikum, Medizinische Klinik und Poliklinikum III | Munich | |
Germany | Universitatsklinikum Ulm | Ulm | |
Greece | University General Hospital Attikon | Chaïdári | |
Greece | Agios Lukas Hospital | Thessaloníki | |
Poland | Szpital Specjalistyczny im Ludwika Rydygiera w Krakowie sp z oo, Department of Clinical Oncology | Kraków | |
Spain | Vall d'Hebron University Hospital, Vall d' Hebron Institute of Oncology (VHIO) | Barcelona | |
Spain | Hospital Universitario HM Sanchinarro | Madrid | |
Spain | La Paz Univeristy Hospital, Universidad Autonoma de Madrid | Madrid | |
Spain | Clinica Universitaria de Navarra | Pamplona | |
Spain | Fundacion Instituto Valenciano de Oncologia | Valencia | |
United Kingdom | The Royal Marsden NHS Foundation Trust | London | |
United States | University of Cincinnati Medical Center | Cincinnati | Ohio |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
United States | University of California San Diego, UCSD | La Jolla | California |
United States | UCLA Medicine Division of Hematology-Oncology | Los Angeles | California |
United States | USC Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Sarah Cannon Research Institute | Nashville | Tennessee |
United States | Thomas Jefferson University City Center and Abington | Philadelphia | Pennsylvania |
United States | University of Pittsburgh Medical Center, UPMC | Pittsburgh | Pennsylvania |
United States | University of Washington / Fred Hutchinson Cancer Center | Seattle | Washington |
United States | Jefferson Health Abington Asplunhd Cancer Pavillion | Willow Grove | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Replimune Inc. | Bristol-Myers Squibb |
United States, Czechia, France, Germany, Greece, Poland, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | LA Cohort: Progression-free Survival | Progression-free survival is defined as the time from the first day of study treatment to the date of progression of disease, which was subsequently confirmed, or death by any cause, whichever occurs first | From Day 1 to documented progression of disease (up to 3 years) | |
Primary | R/M Cohort: Objective Response Rate | Percentage of subjects achieving objective response (complete response + partial response) | From Day 1 to documented progression of disease (up to 3 years) | |
Secondary | LA Cohort: Progression-free Survival Rates at 6 and 12 Months | Progression-free survival is defined as the time from the first day of study treatment to the date of progression of disease, which was subsequently confirmed, or death by any cause, whichever occurs first | From Day 1 to documented progression of disease (up to 12 months) | |
Secondary | LA Cohort: Overall Survival Rate at 1, 2, and 3 Years | Overall survival is defined as the time from the first day of study treatment to the date of death by any cause | From Day 1 to date of death by any cause (up to 3 years) | |
Secondary | LA Cohort: Overall Response Rate and Metabolic Overall Response Rate | Overall Response Rate is the percentage of subjects achieving objective response (complete response + partial response) Metabolic overall response rate is the percentage of subjects achieving objective metabolic response (complete metabolic response + partial metabolic response) | From Day 1 to documented progression of disease (up to 3 years) | |
Secondary | LA Cohort: Complete Response Rate and Metabolic Complete Response Rate at 5-and 8-months Following of Initiation of Radiation Following of Initiation of Radiation | Complete response rate is the percentage of subjects achieving complete response
Metabolic complete response rate is the percentage of subjects achieving metabolic complete response |
From Day 1 to documented progression of disease (up to 8Months Following of Initiation of Radiation) | |
Secondary | LA Cohort: Proportion of Patients Achieving No-Evidence-of-Disease Status by Any Means (Including Salvage Surgery) | No-evidence-of-disease is defined as no evidence of malignancy at any site | From Day 1 to end of study (up to 3 years) | |
Secondary | LA Cohort: Cumulative Incidence of Locoregional Failure | Locoregional Failure is defined as tumor growth or disease infiltration or spread at the primary tumor location and/or at anatomic areas of local and/or regional disease. | From Day 1 to end of study (up to 3 years) | |
Secondary | LA Cohort: Cumulative Incidence of Distant Metastatic Failure | Distant metastatic failure is defined as growth of metastases or new appearance of metastases in lung, bone, liver, other distant organs, and/or distant lymph node stations. | From Day 1 to end of study (up to 3 years) | |
Secondary | LA Cohort: Duration of Clinical Benefit | Duration of clinical benefit is defined as the time from the first day of study treatment to last progression of disease, which was subsequently confirmed or with no further follow-up for response, or death due to any cause, whichever occurs first, for subjects who achieve complete response, partial response, or stable disease | From Day 1 to documented progression of disease (up to 3 years) | |
Secondary | LA Cohort: Summary of Patient-Reported Outcomes Measured by FACT-HNSI-22 | FACT-HNSI-22 is a Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index which consists of 22 items. Each item is scored in a 5 point Likert-type scale: 0=Not at all, 1=A little bit, 2=Some-what, 3=Quite a bit, and 4=Very much. The higher the score, the worse the patient outcome. | From Day 1 to 52 Weeks. | |
Secondary | LA Cohort: Summary of Patient-Reported Outcomes Measured by EQ-5D-5L | EQ-5D-5L is a self-assessed, health related, quality of life questionnaire which consists of 2 pages: EQ-5D descriptive system and EQ visual analogue scale (EQ VAS). The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale which is numbered from 0 to 100. 0 means the worst health the patient can imagine. 100 means the best health the patient can imagine. The higher the score, the better the patient outcome. | From Day 1 to 52 Weeks | |
Secondary | LA Cohort: Frequency, Nature, and Severity of TEAEs and SAEs | Percentage of subjects with TEAEs and SAEs | From Screening through 60 days after last dose of RP3, or 100 days after last dose of nivolumab, or 28 days after last dose of either cisplatin, carboplatin, or paclitaxel, whichever occurs last | |
Secondary | R/M Cohort: Progression-free Survival | Progression-free survival is defined as the time from the first day of study treatment to the date of progression of disease, which was subsequently confirmed, or death by any cause, whichever occurs first | From Day 1 to documented progression of disease (up to 3 years) | |
Secondary | R/M Cohort: Progression-free Survival Rates at 6 and 12 Months | Progression-free survival is defined as the time from the first day of study treatment to the date of progression of disease, which was subsequently confirmed, or death by any cause, whichever occurs first | From Day 1 to documented progression of disease (up to 12 months) | |
Secondary | R/M Cohort: Overall Survival Rates at 1, 2, and 3 Years | Overall survival is defined as the time from the first day of study treatment to the date of death by any cause | From Day 1 to date of death by any cause (up to 3 years) | |
Secondary | R/M Cohort: Duration of Response | Duration of response is defined as the time from documented response until the date of progression of disease, which was subsequently confirmed or with no further follow-up, or death due to any cause, whichever occurs first | From Day 1 to documented progression of disease (up to 3 years) | |
Secondary | R/M Cohort: Duration of Clinical Benefit | Duration of clinical benefit is defined as the time from the first day of study treatment to last progression of disease, which was subsequently confirmed or with no further follow-up for response, or death due to any cause, whichever occurs first, for subjects who achieve complete response, partial response, or stable disease | From Day 1 to documented progression of disease (up to 3 years) | |
Secondary | R/M Cohort: Complete Response Rate | Percentage of subjects achieving a complete response | From Day 1 to documented progression of disease (up to 3 years) | |
Secondary | R/M Cohort: Disease Control Rate | Percentage of patients achieving complete response, partial response, or stable disease | From Day 1 to documented progression of disease (up to 3 years) | |
Secondary | R/M Cohort: Number of Patients Who Undergo Attempted Definitive Resection | Number of Patients Who Undergo Attempted Definitive Resection | From Day 1 to end of study (up to 3 years) | |
Secondary | R/M Cohort: Frequency, Nature, and Severity of TEAEs and SAEs | Percentage of subjects with TEAEs and SAEs | From Screening through 60 days after last dose of RP3, or 100 days after last dose of nivolumab, or 28 days after last dose of either cisplatin, carboplatin, or paclitaxel, whichever occurs last |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02537223 -
Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT00824343 -
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT06022757 -
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05366166 -
Pembrolizumab Plus Olaparib in LA-HNSCC
|
Phase 2 | |
Terminated |
NCT04502888 -
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
|
Phase 1 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Completed |
NCT04098458 -
Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC
|
N/A | |
Not yet recruiting |
NCT04528420 -
Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03997968 -
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05061420 -
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
|
Phase 2 | |
Completed |
NCT04939480 -
Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN
|
Phase 2 | |
Recruiting |
NCT04260802 -
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT04465487 -
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT05845307 -
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
|
Early Phase 1 | |
Active, not recruiting |
NCT04489888 -
A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
|
Phase 4 | |
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
Completed |
NCT04601402 -
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
|
Phase 1 | |
Completed |
NCT00756444 -
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 |